Why Phase 2 sponsors are the most active buyers of clinical services
Phase 2 is where a drug candidate moves from safety in small cohorts to its first real test of efficacy and dose. For a biotech company it is usually the most expensive stage it runs on its own before partnering or pivotal trials, and it is when it buys the most outside help: CROs, clinical sites, central labs, imaging core labs, eCOA and EDC vendors, patient-recruitment firms, drug supply and packaging, and regulatory consultants.
What ClinicalTrials.gov tells you
| Field | Why it matters |
|---|---|
| Lead sponsor and sponsor class | Separates industry sponsors from academic, NIH and other sponsors |
| Phase | Phase 2 and combined Phase 1/2 designs indicate proof-of-concept stage |
| Overall status | Not yet recruiting and recruiting trials are still procuring sites and services; active-not-recruiting trials are in follow-up |
| Conditions and interventions | Therapeutic area and modality — small molecule, antibody, ADC, gene therapy, cell therapy |
| Locations | Countries and sites, useful for regional CROs and site networks |
A search of the registry for industry-sponsored Phase 2 trials that are recruiting, not yet recruiting or active returns more than 5,000 studies. Many sponsors run several trials, so the number of distinct companies is lower; large pharma, Chinese biotechs and small US and European venture-backed companies all appear.
Signals worth watching
- Not yet recruiting trials have often not chosen all sites or vendors.
- Combined Phase 1/2 designs in oncology and gene therapy can expand quickly into dose-expansion cohorts.
- Crowded indications such as MASH, obesity and NSCLC create competition for sites and patients.
Registration is required for most interventional drug trials under FDAAA 801, so the registry is broad, but sponsor names are entered as free text and need normalising across subsidiaries.